Business
Sona Nanotech To Hold Investor Webinar To Discuss Follow-up Data From First-in-human Cancer Therapy Study
Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), will host an investor webinar on Wednesday, March 18th at 3:30pm ET to discuss follow-up data from its first-in-human study of its Targeted Hyperthermia Therapy ("THT") (the "Study") that resulted the generation of immune responses in 8/10 treated and biopsied tumors, with complete responses seen in 6/10. Interested parties can register for this webinar via the following link: https://us06web.zoom.us/webinar/register/WN_D93hv
About this update from Sona Nanotech, Inc.
[{"type":"text","content":"/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/","length":99,"tagName":"p","attribs":{}},{"type":"text","content":"HALIFAX, NS , March 16, 2026 /CNW/ - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), will host an investor webinar on Wednesday, March 18th at 3:30pm ET to discuss follow-up data from its first-in-human study of its Targeted Hyperthermia Therapy ("THT") (the "Study") that resulted the generation of immune responses in 8/10 treated and biopsied tumors, with complete responses seen in 6/10. Interested parties can register for this webinar via the following link: https://us06web.zoom.us/webinar/register/WN_D93hvFoCRO2589nPzO-JIQ","length":599,"tagName":"p"},{"type":"image","alt":"Sona English logo (CNW Group/Sona Nanotech Inc.)","displaySize":"","headline":null,"caption":"Sona English logo (CNW Group/Sona Nanotech Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":335,"url":"https://media.zenfs.com/en/cnwgroup.com/d6fd69aaa87b687d03203ca46ba8a0b9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/sUAxi_Ua.D91yNQSwXDTtQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTU5MDtjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/d6fd69aaa87b687d03203ca46ba8a0b9","width":400,"height":335}},"href":"https://mma.prnewswire.com/media/2934677/Sona_Nanotech_Inc__Sona_Nanotech_To_Hold_Investor_Webinar_To_Dis.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Joining on the webinar will be the study's principal investigator, Dr. Carlos Rojas, executive director of the Centro de Investigacion Clinica, Bradford Hill, along with Sona's CEO, David Regan, and CMO, Dr. Carman Giacomantonio. Data to be presented will include patient follow-up assessments, including evidence that THT treatments generated a clinical response in secondary, untreated tumors, known as an abscopal effect, in a Study patient. This study of ten, late-stage melanoma patients who had failed on standard-of-care immunotherapy protocols, was undertaken to assess the safety, tolerability and efficacy of THT in humans.","length":641,"tagName":"p"},{"type":"text","content":"David Regan, Sona's CEO, commented, "We are excited to be able to share our perspectives on some follow-up data from our...